Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
03 2020
Historique:
received: 28 12 2018
revised: 07 08 2019
accepted: 11 08 2019
pubmed: 29 8 2019
medline: 15 4 2020
entrez: 29 8 2019
Statut: ppublish

Résumé

To estimate the predictive role of faecal haemoglobin (f-Hb) concentration among subjects with faecal immunochemical test (FIT) results below the positivity cut-off for the subsequent risk of advanced neoplasia (AN: colorectal cancer-CRC-or advanced adenoma). Prospective cohort of subjects aged 50-69 years, undergoing their first FIT between 1 January 2004 and 31 December 2010 in four population-based programmes in Italy. All programmes adopted the same analytical procedure (OC Sensor, Eiken Japan), performed every 2 years, on a single sample, with the same positivity cut-off (20 µg Hb/g faeces). We assessed the AN risk at subsequent exams, the cumulative AN detection rate (DR) over the 4-year period following the second FIT and the interval CRC (IC) risk following two negative FITs by cumulative amount of f-Hb concentration over two consecutive negative FITs, using multivariable logistic regression models and the Kaplan-Meier method. The cumulative probability of a positive FIT result over the subsequent two rounds ranged between 7.8% (95% CI 7.5 to 8.2) for subjects with undetectable f-Hb at the initial two tests (50% of the screenees) and 48.4% (95% CI 44.0 to 53.0) among those (0.7% of the screenees) with a cumulative f-Hb concentration ≥20 µg/g faeces. The corresponding figures for cumulative DR were: 1.4% (95% CI 1.3 to 1.6) and 25.5% (95% CI 21.4 to 30.2) for AN; 0.17% (95% CI 0.12 to 0.23) and 4.5% (95% CI 2.8 to 7.1) for CRC. IC risk was also associated with cumulative f-Hb levels. The association of cumulative f-Hb concentration with subsequent AN and IC risk may allow to design tailored strategies to optimise the utilisation of endoscopy resources: subjects with cumulative f-Hb concentration ≥20 µg/g faeces over two negative tests could be referred immediately for total colonoscopy (TC), while screening interval might be extended for those with undetectable f-Hb.

Identifiants

pubmed: 31455608
pii: gutjnl-2018-318198
doi: 10.1136/gutjnl-2018-318198
doi:

Substances chimiques

Hemoglobins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

523-530

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Carlo Senore (C)

SSD Epidemiologia e screening - CPO, University Hospital Città della Salute e della Scienza, Turin, Italy carlo.senore@cpo.it.

Marco Zappa (M)

Clinical Epidemiology Unit, ISPRO, Florence, Italy.

Cinzia Campari (C)

Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Sergio Crotta (S)

AUSL Valle d'Aosta, Aosta, Italy.

Paola Armaroli (P)

SSD Epidemiologia e screening - CPO, University Hospital Città della Salute e della Scienza, Turin, Italy.

Arrigo Arrigoni (A)

University Gastroenterology Unit, Ospedale San Giovanni Antica Sede, Turin, Italy.

Paola Cassoni (P)

Department of Medical Sciences, Universita degli Studi di Torino, Turin, Italy.

Rossana Colla (R)

Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Mario Fracchia (M)

Gastroenterology Unit, Mauriziano Umberto I Hospital, Turin, Italy.

Fabrizio Gili (F)

Colorectal Cancer Screening Laboratory, University Hospital Città della Salute e della Scienza, Turin, Italy.

Grazia Grazzini (G)

Screening Unit, ISPRO, Florence, Italy.

Roberto Lolli (R)

Gastroenterology Unit, Regional Hospital, Aosta, Italy.

Patrizia Menozzi (P)

Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Lorenzo Orione (L)

Screening Unit, ASL CN1, Cuneo, Italy.

Salvatore Polizzi (S)

Screening Unit, ASL TO5, Moncalieri, Italy.

Stefano Rapi (S)

Laboratory, Careggi Hospital, Florence, Italy.

Emilia Riggi (E)

SSD Epidemiologia e screening - CPO, University Hospital Città della Salute e della Scienza, Turin, Italy.

Tiziana Rubeca (T)

Screening Unit, ISPRO, Florence, Italy.

Romano Sassatelli (R)

Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Carmen Visioli (C)

Clinical Epidemiology Unit, ISPRO, Florence, Italy.

Nereo Segnan (N)

SSD Epidemiologia e screening - CPO, University Hospital Città della Salute e della Scienza, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH